Cargando…

How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?

PURPOSE: The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities. MATERIALS AND METHODS: We retrospectively collected data of patients with atypical penile curvature (PC) second...

Descripción completa

Detalles Bibliográficos
Autores principales: Cocci, Andrea, Di Maida, Fabrizio, Russo, Giorgio Ivan, di Mauro, Marina, Cito, Gianmartin, Falcone, Marco, Minervini, Andrea, Cacciamani, Giovanni, Campi, Riccardo, Mari, Andrea, Sessa, Francesco, Mondaini, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Sexual Medicine and Andrology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920074/
https://www.ncbi.nlm.nih.gov/pubmed/31190485
http://dx.doi.org/10.5534/wjmh.190026
_version_ 1783480869369937920
author Cocci, Andrea
Di Maida, Fabrizio
Russo, Giorgio Ivan
di Mauro, Marina
Cito, Gianmartin
Falcone, Marco
Minervini, Andrea
Cacciamani, Giovanni
Campi, Riccardo
Mari, Andrea
Sessa, Francesco
Mondaini, Nicola
author_facet Cocci, Andrea
Di Maida, Fabrizio
Russo, Giorgio Ivan
di Mauro, Marina
Cito, Gianmartin
Falcone, Marco
Minervini, Andrea
Cacciamani, Giovanni
Campi, Riccardo
Mari, Andrea
Sessa, Francesco
Mondaini, Nicola
author_sort Cocci, Andrea
collection PubMed
description PURPOSE: The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities. MATERIALS AND METHODS: We retrospectively collected data of patients with atypical penile curvature (PC) secondary to PD. All patients underwent a modified treatment protocol, consisting of 3 intralesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum PC. Patients were instructed to follow a strict routine, involving daily modeling of erect penis and stretching at the urinary toilette time, two minutes each. Success was defined as a decrease in PC of ≥20° from baseline. RESULTS: Sixty-five patients were included in the analysis. Median age was 59.0 years (interquartile range [IQR], 53.0 to 63.0 years), median curvature 40.0° (IQR, 30.0° to 45.0°) median duration of the disease 12.0 years (IQR, 6.5 to 24.0 years). Fifty-three patients (81.54%) had ventral PC, 7 (10.77%) hourglass PC, and 5 (7.69%) shortening PC. Median changes of PC were −20.0 (IQR, −20.0 to −10.0; p<0.01) in ventral PC, −20.0 (IQR, −20.0 to 0; p<0.01) in hourglass and −15.0 (IQR, −15.0 to −15.0; p<0.01) in shortening PC. At Kruscal–Wallis test, significant differences between groups were not found. The rate of PC success was 56.60% (30/53) in ventral PC, 57.14% (4/7) in hourglass and 20.00% (1/5) in shortening PC (p=0.29). Treatment success was not influenced by characteristics of curvature (odds ratio=0.66; p=0.20). CONCLUSIONS: CCH intralesional injections could represent an effective therapeutic option for the conservative management of patients with atypical PC.
format Online
Article
Text
id pubmed-6920074
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Korean Society for Sexual Medicine and Andrology
record_format MEDLINE/PubMed
spelling pubmed-69200742020-01-01 How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy? Cocci, Andrea Di Maida, Fabrizio Russo, Giorgio Ivan di Mauro, Marina Cito, Gianmartin Falcone, Marco Minervini, Andrea Cacciamani, Giovanni Campi, Riccardo Mari, Andrea Sessa, Francesco Mondaini, Nicola World J Mens Health Original Article PURPOSE: The aim of this study was to evaluate the efficacy of collagenase Clostridium histolyticum (CCH) in patients with Peyronie's disease (PD) suffering from atypical deformities. MATERIALS AND METHODS: We retrospectively collected data of patients with atypical penile curvature (PC) secondary to PD. All patients underwent a modified treatment protocol, consisting of 3 intralesional injections of 0.9 mg of CCH performed at 4-week intervals at the point of maximum PC. Patients were instructed to follow a strict routine, involving daily modeling of erect penis and stretching at the urinary toilette time, two minutes each. Success was defined as a decrease in PC of ≥20° from baseline. RESULTS: Sixty-five patients were included in the analysis. Median age was 59.0 years (interquartile range [IQR], 53.0 to 63.0 years), median curvature 40.0° (IQR, 30.0° to 45.0°) median duration of the disease 12.0 years (IQR, 6.5 to 24.0 years). Fifty-three patients (81.54%) had ventral PC, 7 (10.77%) hourglass PC, and 5 (7.69%) shortening PC. Median changes of PC were −20.0 (IQR, −20.0 to −10.0; p<0.01) in ventral PC, −20.0 (IQR, −20.0 to 0; p<0.01) in hourglass and −15.0 (IQR, −15.0 to −15.0; p<0.01) in shortening PC. At Kruscal–Wallis test, significant differences between groups were not found. The rate of PC success was 56.60% (30/53) in ventral PC, 57.14% (4/7) in hourglass and 20.00% (1/5) in shortening PC (p=0.29). Treatment success was not influenced by characteristics of curvature (odds ratio=0.66; p=0.20). CONCLUSIONS: CCH intralesional injections could represent an effective therapeutic option for the conservative management of patients with atypical PC. Korean Society for Sexual Medicine and Andrology 2020-01 2019-05-29 /pmc/articles/PMC6920074/ /pubmed/31190485 http://dx.doi.org/10.5534/wjmh.190026 Text en Copyright © 2020 Korean Society for Sexual Medicine and Andrology http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cocci, Andrea
Di Maida, Fabrizio
Russo, Giorgio Ivan
di Mauro, Marina
Cito, Gianmartin
Falcone, Marco
Minervini, Andrea
Cacciamani, Giovanni
Campi, Riccardo
Mari, Andrea
Sessa, Francesco
Mondaini, Nicola
How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title_full How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title_fullStr How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title_full_unstemmed How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title_short How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?
title_sort how atypical penile curvature influence clinical outcomes in patients with peyronie's disease receiving collagenase clostridium histolyticum therapy?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920074/
https://www.ncbi.nlm.nih.gov/pubmed/31190485
http://dx.doi.org/10.5534/wjmh.190026
work_keys_str_mv AT cocciandrea howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT dimaidafabrizio howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT russogiorgioivan howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT dimauromarina howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT citogianmartin howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT falconemarco howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT minerviniandrea howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT cacciamanigiovanni howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT campiriccardo howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT mariandrea howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT sessafrancesco howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy
AT mondaininicola howatypicalpenilecurvatureinfluenceclinicaloutcomesinpatientswithpeyroniesdiseasereceivingcollagenaseclostridiumhistolyticumtherapy